19 August 2022 in Materials Today Bio
Polyetheretherketone (PEEK) has gradually become the mainstream material for preparing orthopedic implants due to its similar elastic modulus to human bone, high strength, excellent wear resistance, radiolucency, and biocompatibility. Since the 1990s, PEEK has increasingly been used in orthopedics. Yet, the widespread application of PEEK is limited by its bio-inertness, hydrophobicity, and susceptibility to microbial infections. Further enhancing the osteogenic properties of PEEK-based implants remains a difficult task. This article reviews some modification methods of PEEK in the last five years, including surface modification of PEEK or incorporating materials into the PEEK matrix. For surface modification, PEEK can be modified by chemical treatment, physical treatment, or surface coating with bioactive substances. For PEEK composite material, adding bioactive filler into PEEK through the melting blending method or 3D printing technology can increase the biological activity of PEEK. In addition, some modification methods such as sulfonation treatment of PEEK or grafting antibacterial substances on PEEK can enhance the antibacterial performance of PEEK. These strategies aim to improve the bioactive and antibacterial properties of the modified PEEK. The researchers believe that these modifications could provide valuable guidance on the future design of PEEK orthopedic implants.
11 April 2026 in Cell Death Discovery
Diabetic kidney disease (DKD), a prevalent microvascular complication of diabetes, is a leading cause of chronic kidney disease and end-stage renal disease. Moreover, it plays a crucial role in the morbidity and mortality of diabetic patients. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear hormone receptor superfamily, are key regulators of energy homeostasis, with three distinct subtypes identified: PPARα, PPARγ, and PPARβ/δ. They regulate gene transcription associated with energy metabolism, differentiation, inflammation, and cellular development. In recent years, the increasing incidence of DKD has intensified interest in elucidating the mechanisms and roles of PPARs in DKD. Unlike previous reviews—which focused primarily on individual PPAR subtypes or isolated pathological processes—this review adopts a unique “cell-type-specific perspective.” It systematically elucidates the distinct roles of all three PPAR isotypes (α, γ, and β/δ) across key renal cell types (podocytes, mesangial cells, tubular cells) in DKD. We also explore the potential influence of PPAR genetic polymorphisms on DKD susceptibility. Beyond conventional review frameworks, we propose an innovative therapeutic strategy encompassing PPAR-based multi-target synergistic approaches and nanotechnology-driven cell-specific targeted therapy. This offers novel directions to overcome current therapeutic bottlenecks.
12 June 2026 in Pharmacological Research
The clinical prognosis for osteosarcoma (OS) remains bottlenecked by chemoresistance and pulmonary metastasis. OS features dense infiltration by tumor‑associated macrophages (TAMs) that are hijacked into an immunosuppressive, pro-tumorigenic M2-like phenotype. Overcoming this therapeutic plateau requires a paradigm shift toward active remodeling of the tumor immune microenvironment. This review evaluates the trajectory of TAM-targeted interventions in OS, emphasizing the critical transition from monotypic phagocytosis checkpoint blockade (e.g., CD47, GD2) to multimodal synergistic regimens. We systematically dissect how next-generation nanomedicine, targeted metabolic stressors (ferroptosis, cuproptosis), and pharmacological rewiring can forcibly induce immunogenic cell death and reverse M2 polarization. Addressing the unique reconstructive demands of OS, we spotlight the development of immuno-regenerative scaffolds-bifunctional biomaterials engineered to synchronize post-resection tumor clearance with active osteogenesis. Finally, we highlight how spatial transcriptomics and biomimetic platforms are mapping physical immune-exclusion barriers and novel therapeutic subpopulations. Breaking the OS therapeutic stalemate ultimately demands interventions that breach these spatial architectures and fundamentally reprogram TAMs, guided by real-time functional imaging (e.g., ferumoxytol MRI) and high-resolution biomarkers (e.g., PSME2).
1 July 2026 in International Journal of Nanomedicine
For decades, survival rates in metastatic Osteosarcoma (OS) have starkly plateaued. The persistent failure of immune checkpoint blockade underscores a critical reality: the true therapeutic bottleneck is not merely exhausted T cells, but a profound upstream defect in antigen presentation by Dendritic cells (DCs). To overcome this, this review comprehensively outlines the translational landscape of DC-centric therapeutics in OS, tracing the paradigm shift from foundational ex vivo cellular vaccines to advanced in situ vaccination strategies. Specifically, we highlight how intelligent biomaterials and engineered endogenous vesicles bypass external manipulation to directly prime immunity within the tumor bed. Furthermore, we extensively evaluate state-of-the-art physicochemical nanomedicines—encompassing photothermal, sonodynamic, and metallo-immunologic modalities—engineered to force severe organellar stress, trigger robust immunogenic cell death, and actively reverse the spatial and metabolic paralysis of resident DCs. By coupling these interventions with targeted agents and adoptive cellular therapies, we map a synergistic roadmap for closing the cancer-immunity cycle. Despite remarkable preclinical successes, translating these ultra-complex nanoplatforms faces formidable scale-up challenges, and uncalibrated innate hyper-stimulation risks profound DC exhaustion. Moving forward, transitioning toward logic-gated, metabolically precise delivery systems is imperative to flawlessly repair the innate-adaptive immunity bridge and achieve durable OS eradication.
22 September 2026 in Critical Reviews in Oncology/Hematology